Cohance Lifesciences appoints Yann D'Herve as CEO of CDMO Business
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
Upgrades 2025 full-year CDMO sales and margin outlook
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
The first project will focus on developing an AI-based platform for the sterically guided design of bispecific antibodies
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
Subscribe To Our Newsletter & Stay Updated